Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Safety profile of dirithromycin

G D Sides1, P M Conforti

  • 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.

The Journal of Antimicrobial Chemotherapy
|March 1, 1993
PubMed
Summary

Dirithromycin, an oral antibiotic for infections, demonstrates comparable safety and efficacy to related antibiotics. Its once-daily dosing may improve patient compliance with mild gastrointestinal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chrysotile asbestos fibers in drinking water from asbestos-cement pipe.

Environmental science & technology·2012
Same author

Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections.

The Journal of antimicrobial chemotherapy·2000
Same author

Five-day dirithromycin therapy is as effective as seven-day erythromycin therapy for acute exacerbations of chronic bronchitis.

The Journal of antimicrobial chemotherapy·1999
Same author

Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis.

Antimicrobial agents and chemotherapy·1997
Same author

Clinical efficacy of dirithromycin in patients with bacteremic pneumonia.

Clinical therapeutics·1996
Same author

Tonsillar tissue penetration of dirithromycin after multiple doses.

Journal of clinical pharmacology·1996

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Dirithromycin is a novel oral antibiotic effective against respiratory tract, skin, and soft tissue infections.
  • Once-daily administration of dirithromycin offers potential advantages in patient compliance.
  • Comparison with established antibiotics like erythromycin, roxithromycin, and miocamycin is crucial for understanding its therapeutic role.

Purpose of the Study:

  • To assess the safety and efficacy of dirithromycin in treating various acute infectious illnesses.
  • To compare dirithromycin's safety and efficacy profile against oral erythromycin base, roxithromycin, and miocamycin.
  • To evaluate dirithromycin's safety in elderly patients and its impact on laboratory test results.

Main Methods:

  • A meta-analysis of 66 studies involving 7437 patients conducted over six years in Europe, USA, Israel, and South Africa.
  • Patients received either 500 mg dirithromycin once daily, or comparator antibiotics (erythromycin base, roxithromycin, miocamycin) at specified dosages and frequencies.
  • Therapy duration ranged from 7 to 14 days, with adverse events and laboratory results systematically recorded and compared.

Main Results:

  • Dirithromycin exhibited a safety profile similar to comparator antibiotics, with predominantly mild to moderate gastrointestinal adverse events (99%).
  • Early discontinuation of therapy due to adverse events was infrequent (3-4%) and rarely drug-related (2-3%).
  • The safety of dirithromycin in elderly patients mirrored the overall population, with infrequent and clinically insignificant laboratory abnormalities.

Conclusions:

  • Dirithromycin is a safe and effective oral antibiotic for treating common infections, comparable to erythromycin, roxithromycin, and miocamycin.
  • The favorable safety profile, particularly the low incidence of severe adverse events and the convenience of once-daily dosing, supports its clinical utility.
  • Routine laboratory monitoring is not deemed necessary for patients prescribed dirithromycin due to its infrequent impact on haematological or hepatic function.

Related Experiment Videos